Neuberger Berman Group LLC Has $313.44 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Neuberger Berman Group LLC lowered its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 3.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,923,795 shares of the company's stock after selling 78,823 shares during the quarter. Neuberger Berman Group LLC owned approximately 0.43% of Zoetis worth $313,437,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Callahan Advisors LLC increased its holdings in shares of Zoetis by 90.4% in the 4th quarter. Callahan Advisors LLC now owns 13,105 shares of the company's stock worth $2,135,000 after acquiring an additional 6,221 shares during the period. CIBC Asset Management Inc grew its position in Zoetis by 24.1% in the 4th quarter. CIBC Asset Management Inc now owns 237,369 shares of the company's stock worth $38,617,000 after purchasing an additional 46,050 shares during the last quarter. Pensionfund Sabic increased its stake in shares of Zoetis by 55.6% in the fourth quarter. Pensionfund Sabic now owns 11,200 shares of the company's stock valued at $1,825,000 after purchasing an additional 4,000 shares during the period. PFW Advisors LLC bought a new stake in shares of Zoetis during the fourth quarter valued at approximately $1,764,000. Finally, Schroder Investment Management Group grew its holdings in Zoetis by 2.6% in the 4th quarter. Schroder Investment Management Group now owns 245,726 shares of the company's stock worth $40,036,000 after buying an additional 6,169 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Price Performance

Shares of NYSE ZTS traded down $1.73 during mid-day trading on Tuesday, reaching $149.10. The company had a trading volume of 935,626 shares, compared to its average volume of 2,584,724. The company has a 50-day moving average price of $162.01 and a two-hundred day moving average price of $170.92. The stock has a market cap of $66.53 billion, a PE ratio of 27.26, a P/E/G ratio of 2.78 and a beta of 0.92. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a 1-year low of $139.70 and a 1-year high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The firm had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. On average, equities analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be given a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 1.34%. The ex-dividend date is Monday, April 21st. Zoetis's payout ratio is 36.56%.

Insider Buying and Selling at Zoetis

In related news, Director Willie M. Reed sold 1,210 shares of the business's stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the transaction, the director now directly owns 11,245 shares of the company's stock, valued at approximately $1,868,244.30. The trade was a 9.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Roxanne Lagano sold 326 shares of the business's stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the transaction, the executive vice president now owns 16,107 shares in the company, valued at approximately $2,757,196.26. This represents a 1.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,862 shares of company stock valued at $312,254 in the last three months. 0.16% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on ZTS. Piper Sandler lifted their target price on Zoetis from $200.00 to $205.00 and gave the company an "overweight" rating in a research note on Thursday, February 27th. Stifel Nicolaus cut their price objective on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a research note on Monday. Barclays increased their target price on shares of Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research report on Friday, February 14th. StockNews.com upgraded shares of Zoetis from a "hold" rating to a "buy" rating in a research report on Friday, March 7th. Finally, Morgan Stanley decreased their price objective on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a report on Friday, February 14th. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $214.40.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.